Please login to the form below

Not currently logged in
Email:
Password:

Hepatitis B virus

This page shows the latest Hepatitis B virus news and features for those working in and with pharma, biotech and healthcare.

Gilead targets hep B in half a billion dollar deal with Precision BioSciences

Gilead targets hep B in half a billion dollar deal with Precision BioSciences

Precision’s chief scientific officer, Derek Jantz commented: "Gilead's cure-based approach to hepatitis B is comprehensive and exciting. ... He said: “Gilead is committed to developing innovative therapies to achieve functional cure for patients with

Latest news

  • Ionis must go it alone as GSK ditches polyneuropathy drug Ionis must go it alone as GSK ditches polyneuropathy drug

    GSK isn't giving up on Ionis’pipeline entirely, however. The pharma group is still developing two Ionis drugs for hepatitis B virus in phase II trials.

  • Gilead's Hepatitis B therapy Vemlidy granted EU approval Gilead's Hepatitis B therapy Vemlidy granted EU approval

    The European Commission has granted Gilead's Vemlidy European marketing authorisation, making it the first new hepatitis B virus (HBV) treatment to receive EU approval in nearly a decade. ... infectious diseases, including hepatitis B, while we continue

  • Gilead's hepatitis B virus treatment set for European approval Gilead's hepatitis B virus treatment set for European approval

    Gilead's hepatitis B virus treatment set for European approval. CHMP also recommends diabetes drugs from Sanofi and Novo Nordisk. ... Gilead Sciences' once-daily chronic hepatitis B virus (HBV) therapy Vemlidy has been recommended for the treatment of

  • Priority FDA review for new Gilead HCV combination therapy Priority FDA review for new Gilead HCV combination therapy

    A new combination therapy for hepatitis C virus (HCV) from Gilead Sciences could be approved in the US by the summer after being awarded a priority review by the FDA. ... Meanwhile, Gilead has also reported positive news in the area of hepatitis B virus

  • J&J buys firm seeking hepatitis B cure J&J buys firm seeking hepatitis B cure

    J&J buys firm seeking hepatitis B cure. Acquires Philadelphia-based Novira therapeutics. ... Johnson &Johnson (J&J) has agreed to buy a Pennsylvania biotech company that is trying to develop treatments to cure hepatitis B virus (HBV) infection.

More from news
Approximately 0 fully matching, plus 17 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2018

    hepatitis B virus (HBV). Strategic. collaboration ‐. development. $445m. Innate Pharma/. ... The agreement is for the development of therapies to eliminate the hepatits B virus (HBV) in vivo using the genome editing platform ARCUS.

  • Pharma deals in April 2015 Pharma deals in April 2015

    its SAR3419, an antibody-drug conjugate designed to treat diffuse large B-cell lymphoma (DLBCL) and other blood cancers. ... These are key markets for this product as more than 75% of all HCC cases occur in the APAC region, largely in association with

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Virgo Health

Virgo Health is an award-winning global healthcare communications and medical education agency comprising specialists with some of the best skills,...

Latest intelligence

Marketing to healthcare professionals – what’s the key ingredient missing from most campaigns?
What do you think is the difference between a campaign developed to win a share-of-mind with consumers and a campaign designed to gain the attention of healthcare professionals?...
What everyone forgets about good organisational change in pharma
Natasha Cowan speaks to Daphne Chung, Head of Organisational Transformation, to learn how she ensures smooth organisational change that takes all stakeholders into account....
Live from Singapore: Oncology in APAC - Evaluating the opportunity for novel therapies
Live webinar: Tuesday 11th December 2018,16:00 SGT / 17:00 JST...

Infographics